Mylan launches Advair generic at 70% discount in US
FDA due to make decision in September
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.
GSK also hopes to get IL-5 drug approved in COPD
GSK is aiming to revive its respiratory drugs franchise